China's Biotech Is Quietly Eating Big Pharma's Lunch
Warning! GuruFocus has detected 7 Warning Signs with AKESF.
Multinational pharma isn't waiting around. Pfizer (NYSE:PFE) just cut a $1.2 billion upfront deal with 3SBio. Summit Therapeutics paid $500 million for rights to Akeso's cancer therapy. These aren't niche plays they're big bets on the future. And with China's massive patient pool and streamlined hospital network, companies can run trials in half the time (and at a fraction of the cost) compared to the US. That speed lets Chinese firms launch multiple shots on goal and global players are lining up to license the winners. From cell therapies to obesity drugs, the East is becoming the place where the drug pipeline gets built.
But approval is still a long game. US regulators aren't greenlighting drugs based solely on China trial data not yet. And with rising geopolitical tension, some in Washington are sounding alarms over biotech dependencies. Still, the shift is underway. In just five years, the number of top-ranked Chinese drug innovators has quadrupled. Investors watching this space aren't asking whether China will lead the next wave of biotech innovation. They're asking how soon.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
HSBC posts lower-than-expected profits for first half of 2025
HSBC has warned that it expects lending to 'remain muted' for the rest of 2025 after posting lower-than-expected profits for the first half of the year. Profit before tax fell by 5.7 billion US dollars (£4.3 billion) from the first half of 2024 to 15.8 billion dollars (£11.8 billion). HSBC attributed 3.6 billion dollars (£2.7 billion) of the decline to the sale of its Argentina and Canada operations while the 'dilution and impairment losses' of Bank of Communications accounted for 2.1 billion dollars (£1.6 billion). Profit after tax fell by 30% year on year to 12.4 billion dollars (£9.3 billion). Constant currency profit before tax excluding notable items increased by 900 million dollars (£674 million) to 18.9 billion dollars (£14.2 billion), with a strong performance in international wealth and premier banking and HSBC's Hong Kong business segments cited. Revenue fell by 3.2 billion dollars (£2.4 billion) to 34.1 billion dollars (£25.5 billion), reflecting the disposals of the Canada and Argentina operations. HSBC said results from the first six months of 2025 'included allowances to reflect heightened uncertainty and a deterioration in the forward economic outlook due to geopolitical tensions and higher trade tariffs', and 'included higher spend and investment in technology'. A company statement said: 'The group is well-positioned to manage the changes and uncertainties prevalent within the global environment in which we operate, including in relation to tariffs. 'We have modelled a disruptive tariff scenario that includes significant reductions in policy rates, together with broader macroeconomic deterioration. 'The group remains on track to deliver on our cost target. Our growth in target basis operating expenses in 2025 compared with 2024 remains approximately 3%. 'Our cost target includes the impact of simplification-related saves associated with our announced reorganisation. 'We continue to expect demand for lending to remain muted during 2025.' HSBC Group chief executive officer Georges Elhedery said: 'We're making positive progress in becoming a simple, more agile, focused organisation built on our core strengths. 'In the first half, we continued to execute our strategy with discipline and each of our four businesses sustained momentum in their earnings with each growing revenue. 'This gives us confidence in our ability to deliver our targets. We continue to navigate this period of economic uncertainty and market volatility from a position of strength, putting the changing needs of our customers at the heart of everything we do.'
CNBC
23 minutes ago
- CNBC
Euro hovers near one-month lows after trade deal, focus switches to Fed
The euro steadied near its lowest in a month on Wednesday, nursing steep losses this week as investors counted the cost of the U.S.-EU trade pact and looked ahead to policy meetings from the Federal Reserve and the Bank of Japan. U.S. and Chinese officials agreed to seek an extension of their 90-day tariff truce on Tuesday, following two days of what both sides described as constructive talks in Stockholm. No major breakthroughs were announced, and U.S. officials said it was up to President Donald Trump to decide whether to extend a truce that expires on August 12. The Sino-U.S. talks come after a framework deal between the U.S. and EU was announced on Sunday. The accord has evoked a mix of relief and concern from Europe, as the agreement was lopsided and skewed towards the United States. "Markets seem to be increasingly interpreting trade agreements as symbolic and tactical rather than structural resolution," said Charu Chanana, chief investment strategist at Saxo in Singapore. "With terms often vague and enforcement mechanisms weak, investors are assigning lower market beta to these negotiations unless backed by concrete detail." The euro was 0.12% higher at $1.1558 in early trading after dropping for the first two days of the week and hitting a one-month low of $1.15185 on Tuesday. The euro is up 11.7% since the start of the year but on course for its first monthly drop this year. The single currency has benefited this year from the dollar losing its luster due to Trump's erratic trade policies, prompting investors to look for alternatives. Sterling was at $1.3358 and the Australian dollar last bought $0.6517. The offshore yuan was little changed at 7.178 per U.S. dollar. The Japanese yen firmed a bit to 148.20 per dollar. That left the dollar index, which measures the U.S. currency against six others, at 98.815, hovering near a one-month high. The index is set to record its first month of gains this year. Investor focus will now switch to central bank meetings, with the Fed due to announce its policy decision later on Wednesday. The Fed is widely expected to stand pat, making comments from Chair Jerome Powell crucial to gauge the policy path. The policy decision comes in the wake of Trump's constant demands for rate cuts, which have coincided with an unrelenting campaign of attacks on Powell by the president and administration officials. There is speculation that Governor Christopher Waller and Vice Chair for Supervision Michelle Bowman could issue dissents if the Fed on Wednesday holds the policy rate steady for the fifth time since December. "While dissenting isn't uncommon, the dissents at this week's meeting may get more focus because Trump has made it crystal clear that he thinks the FOMC should be lowering interest rates," said Kristina Clifton, a senior economist at the Commonwealth Bank of Australia in Sydney. "Dissents at this meeting may be judged as political and put a dent in perceptions of the FOMC's independence." The BOJ is also expected to stand pat and the spotlight will be on comments from Governor Kazuo Ueda as investors hope the recent trade deal between Japan and the U.S. paves the way for the central bank to raise interest rates again this year.
CNBC
23 minutes ago
- CNBC
Oil steady after big gains on Trump's Russia ultimatum
Oil prices ticked up in early trading on Wednesday after rising more than 3% in the previous session as potential supply shortages came into focus after U.S. President Donald Trump gave Moscow an abbreviated deadline toward ending the war in Ukraine. Brent crude futures rose 14 cents, or 0.19%, to $72.65 a barrel by 0048 GMT while U.S. West Texas Intermediate crude climbed 2 cents, or 0.03%, to $69.23 a barrel. Both contracts had settled at their highest since June 20 on Tuesday. On Tuesday, Trump said he would start imposing measures on Russia, including 100% secondary tariffs on its trading partners, if it did not make progress on ending the war within 10-12 days, moving up an earlier 50-day deadline. "Effective secondary 100% tariffs would lead to a dramatic shift in the oil market. A number of key buyers of Russian oil would likely be reluctant to continue purchases, particularly large U.S. trading partners," ING analysts said in a note. "While this gives OPEC+ room to start unwinding additional tranches of supply cuts, it would still leave the market in deficit under a worst-case scenario." The U.S. had warned China, the largest buyer of Russian oil, that it could face huge tariffs if it continues buying, Treasury Secretary Scott Bessent told a news conference in Stockholm where the U.S. was holding trade talks with the EU. JP Morgan analysts said in a note that while China was not likely to comply with U.S. sanctions, India has signaled it would do so, potentially putting 2.3 million barrels per day of Russian oil exports at risk. The U.S. and EU averted a trade war with a deal that included 15% U.S. tariffs on European imports, easing concerns about the impact of trade tensions on economic growth and offering further support to oil prices. In Venezuela, foreign partners of state oil company PDVSA are still waiting for authorizations from the U.S. to operate in the sanctioned country after talks on the subject last week, which could return some supply to the market, potentially easing pressure for prices to rise.
